nodes	percent_of_prediction	percent_of_DWPC	metapath
Lofexidine—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0693	0.0693	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0571	0.0571	CbGpPWpGaD
Lofexidine—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0487	0.0487	CbGpPWpGaD
Lofexidine—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0473	0.0473	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0449	0.0449	CbGpPWpGaD
Lofexidine—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0441	0.0441	CbGpPWpGaD
Lofexidine—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.041	0.041	CbGpPWpGaD
Lofexidine—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0398	0.0398	CbGpPWpGaD
Lofexidine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0383	0.0383	CbGpPWpGaD
Lofexidine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0372	0.0372	CbGpPWpGaD
Lofexidine—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.037	0.037	CbGpPWpGaD
Lofexidine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0346	0.0346	CbGpPWpGaD
Lofexidine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0322	0.0322	CbGpPWpGaD
Lofexidine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0313	0.0313	CbGpPWpGaD
Lofexidine—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0309	0.0309	CbGpPWpGaD
Lofexidine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0291	0.0291	CbGpPWpGaD
Lofexidine—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0259	0.0259	CbGpPWpGaD
Lofexidine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0243	0.0243	CbGpPWpGaD
Lofexidine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0204	0.0204	CbGpPWpGaD
Lofexidine—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0101	0.0101	CbGpPWpGaD
Lofexidine—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00984	0.00984	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0094	0.0094	CbGpPWpGaD
Lofexidine—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00916	0.00916	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00913	0.00913	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00891	0.00891	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0085	0.0085	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00806	0.00806	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00796	0.00796	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00782	0.00782	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00773	0.00773	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00739	0.00739	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00729	0.00729	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.0072	0.0072	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00717	0.00717	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00668	0.00668	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00633	0.00633	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00615	0.00615	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00614	0.00614	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00596	0.00596	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00596	0.00596	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00573	0.00573	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00555	0.00555	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0051	0.0051	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00482	0.00482	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00468	0.00468	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00468	0.00468	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.00462	0.00462	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00436	0.00436	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00401	0.00401	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00389	0.00389	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00347	0.00347	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00337	0.00337	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00315	0.00315	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00314	0.00314	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00306	0.00306	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00305	0.00305	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00285	0.00285	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00272	0.00272	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00265	0.00265	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00247	0.00247	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00246	0.00246	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0024	0.0024	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00224	0.00224	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0022	0.0022	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00199	0.00199	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00186	0.00186	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00181	0.00181	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00173	0.00173	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00168	0.00168	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00157	0.00157	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00146	0.00146	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00142	0.00142	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00132	0.00132	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00118	0.00118	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000926	0.000926	CbGpPWpGaD
